These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9292911)

  • 21. Airway clearance strategies in cystic fibrosis and non-cystic fibrosis bronchiectasis.
    Main E; Grillo L; Rand S
    Semin Respir Crit Care Med; 2015 Apr; 36(2):251-66. PubMed ID: 25826592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.
    Moskowitz SM; Gibson RL; Effmann EL
    Pediatr Radiol; 2005 Aug; 35(8):739-57. PubMed ID: 15868140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early pulmonary disease in cystic fibrosis.
    Accurso FJ
    Curr Opin Pulm Med; 1997 Nov; 3(6):400-3. PubMed ID: 9391757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale for hypertonic saline therapy for cystic fibrosis lung disease.
    Tarran R; Donaldson S; Boucher RC
    Semin Respir Crit Care Med; 2007 Jun; 28(3):295-302. PubMed ID: 17562499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
    VanDevanter DR; Craib ML; Pasta DJ; Millar SJ; Morgan WJ; Konstan MW;
    Pediatr Pulmonol; 2018 Jan; 53(1):43-49. PubMed ID: 29064184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dornase alfa in early cystic fibrosis lung disease.
    Robinson PJ
    Pediatr Pulmonol; 2002 Sep; 34(3):237-41. PubMed ID: 12203856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.
    Nash EF; Stephenson A; Ratjen F; Tullis E
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007168. PubMed ID: 19160327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammation and cystic fibrosis pulmonary disease.
    Kennedy MJ
    Pharmacotherapy; 2001 May; 21(5):593-603. PubMed ID: 11349748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucus structure and properties in cystic fibrosis.
    Rubin BK
    Paediatr Respir Rev; 2007 Mar; 8(1):4-7. PubMed ID: 17419972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled hypertonic saline as a therapy for cystic fibrosis.
    Elkins MR; Bye PT
    Curr Opin Pulm Med; 2006 Nov; 12(6):445-52. PubMed ID: 17053496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis.
    Suri R
    BioDrugs; 2005; 19(3):135-44. PubMed ID: 15984899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The activin A antagonist follistatin inhibits cystic fibrosis-like lung inflammation and pathology.
    Hardy CL; King SJ; Mifsud NA; Hedger MP; Phillips DJ; Mackay F; de Kretser DM; Wilson JW; Rolland JM; O'Hehir RE
    Immunol Cell Biol; 2015 Jul; 93(6):567-74. PubMed ID: 25753271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy.
    App EM; King M; Helfesrieder R; Köhler D; Matthys H
    Am Rev Respir Dis; 1990 Mar; 141(3):605-12. PubMed ID: 2310093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dornase alfa (Pulmozyme).
    Wagener JS; Kupfer O
    Curr Opin Pulm Med; 2012 Nov; 18(6):609-14. PubMed ID: 22990660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cystic fibrosis: a disease of vulnerability to airway surface dehydration.
    Boucher RC
    Trends Mol Med; 2007 Jun; 13(6):231-40. PubMed ID: 17524805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa].
    Derelle J; Bertolo-Houriez E; Marchal F; Weber M; Virion JM; Vidailhet M
    Arch Pediatr; 1998 Apr; 5(4):371-7. PubMed ID: 9759155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New aerosol delivery devices for cystic fibrosis.
    Kesser KC; Geller DE
    Respir Care; 2009 Jun; 54(6):754-67; discussion 767-8. PubMed ID: 19467162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease.
    Gehrig S; Duerr J; Weitnauer M; Wagner CJ; Graeber SY; Schatterny J; Hirtz S; Belaaouaj A; Dalpke AH; Schultz C; Mall MA
    Am J Respir Crit Care Med; 2014 May; 189(9):1082-92. PubMed ID: 24678594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis.
    Knowles MR; Olivier K; Noone P; Boucher RC
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S65-9. PubMed ID: 7533608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period.
    Shah PL; Conway S; Scott SF; Rainisio M; Wildman M; Stableforth D; Hodson ME
    Respiration; 2001; 68(2):160-4. PubMed ID: 11287830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.